Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
7,624 results
- BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01079234).
- BEGSIndependent statistical analysis of Benralizumab for Eosinophilic Gastritis (BEGS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03473977).
- Behavior During Experimentally Induced Pain: Complete Statistical AnalysisIndependent statistical analysis of Behavior During Experimentally Induced Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01594528).
- Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01351766).
- Behavioral Economic Treatment to Enhance Rural (BETTER) Living: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Economic Treatment to Enhance Rural (BETTER) Living: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05235971).
- Behavioral Economics and Communication: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Economics and Communication: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05918393).
- Behavioral Insights to Encourage Judicious Prescribing of Opioids: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Insights to Encourage Judicious Prescribing of Opioids: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02790476).
- Beige Fat, Energy, and the Natriuretic Peptide System: Complete Statistical AnalysisIndependent statistical analysis of Beige Fat, Energy, and the Natriuretic Peptide System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04357964).
- BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: Complete Statistical AnalysisIndependent statistical analysis of BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: primary endpoint…
- Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04676360).
- Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02152345).
- Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin:…
- BELLE-4Independent statistical analysis of A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation: primary endpoint results,…
- Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin’s Lymphoma(NHL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00426855).
- Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00705250).
- Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BENEFITIndependent statistical analysis of Crossover Comparison of MultiHance and Dotarem: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02070380).
- Benefit of Assistive Listening Device for Lateralization: Complete Statistical AnalysisIndependent statistical analysis of Benefit of Assistive Listening Device for Lateralization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05072457).
- Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: Complete Statistical AnalysisIndependent statistical analysis of Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BENEGENE-2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B: primary endpoint results,…
- BenidipineTRIndependent statistical analysis of Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06808321).
- Benzocaine Gel Toothache Dose-Response Study: Complete Statistical AnalysisIndependent statistical analysis of Benzocaine Gel Toothache Dose-Response Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00474175).
- Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram: Complete Statistical AnalysisIndependent statistical analysis of Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01925469).
- Berinert (C1INH) vs Placebo for DGF/IRI: Complete Statistical AnalysisIndependent statistical analysis of Berinert (C1INH) vs Placebo for DGF/IRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04696146).
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BESPOKEIndependent statistical analysis of A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BESTIndependent statistical analysis of Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study-: Complete Statistical AnalysisIndependent statistical analysis of BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study-: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00351741).
- BESTFITIndependent statistical analysis of BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01903265).
- BESTOWIndependent statistical analysis of Binge Eating Syndrome Treatment for Older Women (BESTOW): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05806788).
- BETAIndependent statistical analysis of Behavioral Economics to Improve Antihypertensive Therapy Adherence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04029883).
- Beta Events and Sensory Perception: Complete Statistical AnalysisIndependent statistical analysis of Beta Events and Sensory Perception: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04062318).
- Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison: Complete Statistical AnalysisIndependent statistical analysis of Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01002456).
- Beta-blockers in Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Beta-blockers in Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02507011).
- BETTERIndependent statistical analysis of Bringing Education Through Technology, Empathic Listening, and Research: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05214118).
- BevacizumabIndependent statistical analysis of A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00401817).
- Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01125046).
- Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00055692).
- Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…